Table 3.
Randomized Clinical Trials of Sodium-Glucose Cotransporter-2 Inhibitors
| Drug | EMPA-REG Outcome | CANVAS Program | DECLARE-TIMI 58 | CREDENCE |
|---|---|---|---|---|
| Empagliflozin | Canagliflozin | Dapagliflozin | Canagliflozin | |
| Median follow-up time, year | 3.1 | 2.4 | 4.2 | 2.6 |
| Trial participants | 7020 | 10,142 | 17,160 | 4401 |
| Patients with established atherosclerotic cardiovascular disease (ratio: %) | 7020 (100%) | 6656 (65.6%) | 6974 (40.6%) | 2220 (50.4%) |
| Patients with a history of heart failure (ratio: %) | 706 (10.1%) | 1461 (14.4%) | 1724 (10.0%) | 652 (14.8%) |
| Patients with eGFR<60 mL/min per 1.73 m2 (ratio: %) | 1819 (25.9%) | 2039 (20.1%) | 1265 (7.4%) | 2592 (58.9%) |
Abbreviations: EMPA-REG OUTCOME, empagliflozin cardiovascular outcome event trial in type-2 diabetes mellitus patients – removing excess glucose; CANVAS, SGLT2 inhibitors could improve renal prognosis in patients with atherosclerotic disease. Second, in the subsequent canagliflozin cardiovascular assessment study; DECLARE-TIMI 58, dapagliflozin effect on cardiovascular events – thrombolysis in myocardial infarction 58; CREDENCE, canagliflozin and renal events in diabetes with established nephropathy clinical evaluation.